In this research study, our main goal for the ipilimumab portion of the study is to determine the highest dose of ipilimumab that can be given safely in several courses and to determine what side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF).
- acute myeloid leukemia (AML)
- chronic myelomonocytic leukaemia (CMML)
- myelodysplastic syndromes (MDS)
- myeloproliferative neoplasms (MPN)